Explore articles and information related to GLP-1 drug risks and current litigation surrounding semaglutide manufacturers Ozempic, Wegovy, Rybelsus & Mounjaro.
Federal court mandates gastric emptying studies for all Ozempic gastroparesis lawsuits. If you have a confirmed diagnosis through scintigraphy, breath test, or WMC, learn how this August 2025 ruling affects your compensation claim.
A recent Harvard Medical School study has revealed a potential link between a rare but serious eye condition and semaglutide, the active ingredient in popular weight loss and diabetes medications such as Ozempic, Rybelsus, Wegovy, and Mounjaro.
GLP-1 RA litigation preps for Science Day where experts will discuss the science and the reported side effects related to these diabetes and weight loss drugs.
Ozempic Litigation Update: Details from the April 18, 2024, Status Conference Overview of the Status Conference On April 18, 2024, Judge Gene E.K. Pratter presided
This article explores the safety profile of GLP-1 drugs used for type 2 diabetes and weight loss, following an FDA review that identified potential gastrointestinal risks.
Overview of the Ozempic Litigation The federal judge overseeing the Ozempic litigation, Hon. Gene E.K. Pratter, conducted the first status conference on March 14, 2024,
Explore eligibility for filing an Ozempic lawsuit focused on severe side effects like gastroparesis and intestinal blockages. Understand the criteria and legal options available for affected patients and their families seeking compensation.
Discover the unseen risks of Ozempic and other GLP-1 drugs, as revealed by internal FDA documents. Uncover the truth fueling Ozempic lawsuits and learn how The Levensten Law Firm is advocating for affected patients.
Ozempic: More Than Weight Loss – Know the Risks. Ozempic, famed for diabetes and weight management, harbors risks like gallbladder issues, intestinal obstruction, and more. Understand these serious implications before considering Ozempic.
